Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer

Table 3 Clinical response rates for locoregional recurrent breast cancer (3 months after completion of concurrent radiation therapy and paclitaxel)

^a2 patients with progressive disease had tumor regression immediately after completion of concurrent radiation therapy and paclitaxel, but new recurrent nodules occurred in the treatment fields at 3 months after completion of concurrent chemoradiation

ISSN: 1748-717X